UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2015
Commission File Number: 001-36596
Trillium Therapeutics Inc.
(Translation of registrant’s name into English)
96 Skyway Avenue
Toronto, Ontario M9W 4Y9
Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ¨ Form 40-F x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ¨
INCORPORATION BY REFERENCE
Exhibit 1.1 to this Form 6-K is hereby incorporated by reference as an exhibit to the registration statement on Form F-1 of Trillium Therapeutics Inc. (File No. 333-202665).
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Trillium Therapeutics Inc. | ||||||
Date: April 1, 2015 | ||||||
By: | /s/ James Parsons | |||||
Name: | James Parsons | |||||
Title: | Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit | Description | |
1.1 | Underwriting Agreement, dated March 31, 2015 | |
99.1 | News release, dated April 1, 2015 |